Improving the in vivo duration of 5-lipoxygenase inhibitors: Application of an in vitro glucuronosyltransferase assay

Drug Metabolism and Disposition

Volumn 25, Issue 9, 1997, Pages 1032-1038

  Bouska, Jennifer J ^a   Bell, Randy L ^b   Goodfellow, Carole L ^b   Stewart, Andrew O ^b   Brooks, Clint D W ^b   Carter, George W ^b  

^a ABBOTT LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATRELEUTON; LIPOXYGENASE INHIBITOR; N [3 [5 (4 FLUOROPHENYLMETHYL) 2 THIENYL] 1 METHYL 2 PROPYNYL] N HYDROXYUREA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG CLEARANCE; DRUG CONFORMATION; DRUG PROTEIN BINDING; DRUG STABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; MICHAELIS CONSTANT; MONKEY; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; GLUCURONOSYLTRANSFERASE; HALF-LIFE; HUMANS; HYDROXYUREA; LIPOXYGENASE INHIBITORS; MACACA FASCICULARIS; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; MACACA FASCICULARIS;

EID: 0030833366     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. B. Samuelsson: Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220, 568-575 (1983).
2. E. Israel, J. Cohn, L. Dube, and J. M. Drazen: Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. J.A.M.A. 275, 931-936 (1996).
3. R. A. Braeckmann, G. Richard Granneman, P. R. Rubin, and J. W. Kesterson: Pharmacokinetics and metabolism of the new 5-lipoxygenase inhibitor A-64077 after single oral administration in man. J. Clin. Pharmacol. 29, 837 (1989).
4. J. B. Summers, H. Mazdiyasni, J. H. Holms, J. D. Ratajczyk, R. D. Dyer, and G. W. Carter: Hydroxamic acid inhibitors of 5-lipoxygenase. J. Med. Chem. 30, 574-580 (1987).
5. P. Rubin, L. Dube, R. A. Braeckmann, L. Swanson, R. Hanson, D. H. Albert, and G. W. Carter: Pharmacokinetics, safety and ability to diminish leuko triene synthesis by zileuton, an inhibitor of 5-lipoxygenase. In "Progress in Inflammation Research and Therapy" (N. R. Ackerman, R. J. Bonney, and A. F. Welton, eds.), pp. 103-116. Birkhauser Verlag, Basel, 1991.
6. G. W. Carter, P. R. Young, D. H. Albert, J. Bouska, R. Dyer, R. L. Bell, J. B. Summers, and D. W. Brooks: 5-Lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther. 256, 929-937 (1990).
7. R. L. Bell, J. B. Bouska, P. E. Malo, C. Lanni, R. R. Harris, E. R. Otis, A. O. Stewart, D. W. Brooks, and G. W. Carter: Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. J. Pharmacol. Exp. Ther. 272, 724-731 (1995).
8. A. David Rodrigues: Use of in vitro human metabolism studies in drug development. Biochem. Pharmacol. 48, 2147-2156 (1994).
9. M. Mistry and J. Brian Houston: Glucuronidation in vitro and in vivo. Drug Metab. Dispos. 15, 710-717 (1987).
10. J. Brian Houston: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47, 1469-1479 (1994).
11. G. R. Wilkinson: Clearance approaches to pharmacology. Pharmacol. Rev. 39, 1-47 (1987).
12. J. A. Waldhausen, F. L. Abel, and E. E. Selkurt: Splanching blood flow in the monkey during hemorrhagic shock. Surg. Forum 15, 7-8 (1964).
13. D. W. Brooks, J. B. Summers, A. O. Stewart, R. L. Bell, J. B. Bouska, C. Lanni, P. R. Young, P. Rubin, and G. W. Carter: Novel inhibitors of leukotriene biosynthesis. In "Perspectives in Medicinal Chemistry" (B. Testa, E. Kyburz, W. Fuhrer, and R. Giger, eds.), pp. 119-134. Verlag Helvetica Chimica Acta, Basel, 1993.
14. G. W. Carter, R. L. Bell, K. Marsh, C. Lanni, W. M. Awni, J. B. Bouska, A. O. Stewart, R. Hanson, L. Dube, and D. W. Brooks: Stereoselective metabolism of the 5-lipoxygenase inhibitor A-78773. Ann N.Y. Acad. Sci. 744, 262-272 (1994).
15. D. J. Sweeny, J. B. Bouska, J. Machinist, R. L. Bell, G. W. Carter, S. Cepa, and H. N. Nellans: Glucuronidation of zileuton (A-64077) by human hepatic microsomes. Drug Metab. Dispos. 20, 328-329 (1992).
16. D. J. Sweeny and H. N. Nellans: Stereoselective glucuronidation of zileuton isomers by human hepatic microsomes. Drug Metab. Dispos. 23, 149-153 (1995).
17. J. M. Machinist, M. D. Mayer, M. S. Shet, J. L. Ferrero, and A. David Rodrigues: Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite. Abbott-66193. Drug Metab. Dispos. 23, 1163-1174 (1995).
18. J. M. Machinist, M. J. Kulkulka, and B. A. Bopp: In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite. Clin. Pharmacokinet. 29 (Suppl. 2). 34-41 (1995).
19. S.-H. L. Chiu: The use of in vitro metabolism studies in the understanding of new drugs. J. Pharmacol. Toxicol. Methods 29, 77-83 (1993).
20. C. D. W. Brooks, A. O. Stewart, A. Basha, P. Bhatia, J. D. Ratajczyk, J. G. Martin, R. A. Craig, T. Kolasa, J. B. Bouska, C. Lanni, R. R. Harris, P. E. Malo, G. W. Carter, and R. L. Bell: (R)-(+)-N-[3-[5-[(4-Fluorophenyl)methyl]-2-thienyl]-l-methyl-2-propynyl]-N- hydroxyurea (ABT-761), a second generation 5-lipoxygenase inhibitor. J. Med. Chem. 38, 4768-4775 (1995).